The United States is shouldering a growing share of the world’s drug bill because foreign governments squeeze prices elsewhere, and that imbalance should be treated as a trade problem, not just a health policy issue. This piece explains how overseas price controls shift costs onto American patients, why those rules qualify as trade distortions, and why Washington should use trade law tools to push for a fairer global split of pharmaceutical costs. It highlights recent moves in Germany and other allies that make the problem worse and outlines the case for a formal trade investigation. The bottom line is simple: if partners keep offloading costs, the U.S. market will keep carrying the load and innovation will suffer.
Americans already pay more for healthcare than citizens of any other country, and the reasons run from insurance market quirks to legal costs. One factor that doesn’t get nearly enough attention is that many foreign governments maintain pricing systems that cap what they’ll pay for medicines. Those caps mean U.S. patients effectively subsidize the global research and development that produces the drugs they use.
Call it what it is: a trade distortion. When governments force prices below what a market would tolerate, they pull revenue out of the global pool that pays for new treatments. The proper response from a free market standpoint is to treat those policies the way we treat other discriminatory or unreasonable foreign practices — with trade remedies that force a reckoning.
Countries like Germany, France and Japan use a stew of rules — mandatory rebates, price-volume controls and strict reimbursement limits — that push down prices and hand manufacturers an ultimatum: accept those terms or lose access. Manufacturers usually take the deal because getting shut out of big markets is worse than accepting a lower price, and the net effect is that revenues that might have been spread globally are instead concentrated in the American market.
HHS SEC ROBERT F KENNEDY JR: AMERICAN PATIENTS PAY MORE SO OTHERS CAN PAY LESS — THAT STOPS NOW That sentence captures a political moment, and it underscores why Republican policymakers have turned to trade tools. If allies won’t pay their part, we should not be shy about defending American consumers through legal channels that are already on the books.
The consequence is predictable: higher U.S. prices. When global returns shrink because of foreign price caps, companies must recoup the costs elsewhere. The United States, with its larger and less-restricted market, picks up the slack. Those higher prices are not a mysterious market failure; they are the arithmetic of cost-shifting.
Look at Germany for a warning. Recent proposals would broaden mandatory rebates, tighten price-volume clauses that trigger automatic cuts as sales rise, and permit selective contracting that channels reimbursements to the lowest-cost options within drug classes. Moves like that don’t just squeeze a few margins; they compress the whole pricing structure and encourage other nations to copy the model.
France, Japan and Switzerland are already eyeing similar changes, so this is more than a one-off dispute. When a cluster of developed economies converges on the same low-price approach, the United States ends up buying a disproportionate share of innovation. That outcome is neither fair nor sustainable from a market or national-interest perspective.
Fortunately, the law provides remedies. Section 301 of the Trade Act of 1974 lets the United States investigate and respond to foreign government practices that are unreasonable, discriminatory or burden U.S. commerce. It has been used before against non-tariff barriers such as unfair intellectual property rules and digital taxes, and the same framework applies to pricing systems that distort global pharmaceutical revenues.
The Trump administration has signaled a readiness to push back, through voluntary Most Favored Nation-type approaches and reported consideration of Section 301 steps. Those measures aim to rebalance costs without imposing domestic price controls, and they show a willingness to move the conversation beyond healthcare policy into trade enforcement. That shift is exactly what’s needed if partner countries won’t otherwise change.
There is public support for action, and a clear interest for Republicans to lead on this: protect American patients, defend innovation, and use the tools available to secure fair treatment in trade relationships. If allies insist on exporting the cost of R&D, Washington should respond with the full toolbox to restore balance and make sure the burden of innovation isn’t dumped on U.S. consumers alone.
